ArticleNeurology2017
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
Open access · hybridAbstract read
In one paragraph
Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 151 citations in OpenAlex.
- Early Prediction of Parkinson's Disease Progression by Integrating Research Cohort and Real-World Data Using Knowledge-Anchored Graph Learning.medRxiv : the preprint server for health sciences · 2026Article
- Peripheral Inflammatory Biomarkers in Parkinson's Disease: Clinical Correlations and Stratification.Cellular and molecular neurobiology · 2026Article
- Tau protein in Parkinson's disease: advances in phosphoproteomics and molecular dynamics simulations.Frontiers in aging neuroscience · 2026Review
- Emerging biomarkers for Parkinson's disease in biological fluids.Frontiers in aging neuroscience · 2026Review
- Predicting Parkinson's disease and its progression based on radiomics in T1-weight images and α‑synuclein in cerebrospinal fluid.NPJ Parkinson's disease · 2025Article
- Article
- Longitudinal Multimodal Functional Imaging: An Essential Tool for Visualizing Pathologic Progression in Parkinson's Disease.Journal of movement disorders · 2025Article
- Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer's disease.Molecular neurodegeneration · 2025Article
- A personalised and comprehensive approach is required to suppress or replenish SNCA for Parkinson's disease.NPJ Parkinson's disease · 2025Review
- Recent Advances in Co-Condensation and Co-Aggregation of Amyloid Proteins Linked to Neurodegenerative Diseases.Current protein & peptide science · 2025Review
- Early diagnosis of Parkinson's disease: biomarker study.Frontiers in aging neuroscience · 2025Review
- Comparative analysis of neuroinflammatory pathways in Alzheimer's disease, Parkinson's disease, and multiple sclerosis: insights into similarities and distinctions.Frontiers in neuroscience · 2025Review
- Cerebrospinal fluid tau and disease progression in early Parkinson's disease: an 8-year longitudinal study.Journal of neurology · 2024Article
- Letter in reply: before biomolecules are claimed as biomarkers of COVID-19, their criteria must be met.Future microbiology · 2024Article
- Review
- LRRK2-Associated Parkinsonism With and WithoutmedRxiv : the preprint server for health sciences · 2024Article
- Identification of Parkinson's disease PACE subtypes and repurposing treatments through integrative analyses of multimodal data.NPJ digital medicine · 2024Article
- Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions.Nature communications · 2024Review
- An interactive web application to identify early Parkinsonian non-tremor-dominant subtypes.Journal of neurology · 2024Article
- Associations of Multimorbidity with Cerebrospinal Fluid Biomarkers for Neurodegenerative Disorders in Early Parkinson's Disease: A Crosssectional and Longitudinal Study.Current Alzheimer research · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Brit MollenhauerFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego. brit.mollenhauer@med.uni-goettingen.de.
Chelsea J Caspell-GarciaFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.
Christopher S CoffeyFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.
Peggy TaylorFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.
Leslie M ShawFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.
John Q TrojanowskiFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.
Andy SingletonFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.
Mark FrasierFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.
Kenneth MarekFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.
Douglas GalaskoFrom the Department of Neurology (B.M.), University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M.), Kassel, Germany; Department of Biostatistics (C.J.C.-G., C.S.C.), College of Public Health, University of Iowa, Iowa City; BioLegend Inc. (P.T.), San Diego, CA; Department of Pathology & Laboratory Medicine (L.M.S., J.Q.T.), Center for Neurodegenerative Disease Research, Institute on Aging (L.M.S. , J.Q.T.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (J.Q.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Molecular Genetics Section (A.S.), Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD; The Michael J. Fox Foundation for Parkinson's Research (M.F.), New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; and Department of Neurosciences (D.G.), University of California, San Diego.
Parkinson's Progression Marker Initiative
University of Iowa · USParacelsus Elena Klinik Kassel · DE
Funding
VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4MUPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1MProject IV: "Alpha-Synuclein Strains & Diverse Synucleinopathies"P50NS053488 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2007 to 2017
$20.9MTR&D3: Intrinsic Surface MappingP41EB015922 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VAN HORN, JOHN DARRELL · 2012 to 2022
$14.1MGenome wide SNP analysis in Parkinson's diseaseZIAAG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$12.6MCharacterization of Normal Genomic VariabilityZIAAG000932 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$11.3MNIA NIH HHS P30 AG010124NIA NIH HHS P50 AG005131NIBIB NIH HHS P41 EB015922NINDS NIH HHS P50 NS053488
Abstract
objectiveTo analyze longitudinal levels of CSF biomarkers in drug-naive patients with Parkinson disease (PD) and healthy controls (HC), examine the extent to which these biomarker changes relate to clinical measures of PD, and identify what may influence them.
methodsCSF α-synuclein (α-syn), total and phosphorylated tau (t- and p-tau), and β-amyloid 1-42 (Aβ42) were measured at baseline and 6 and 12 months in 173 patients with PD and 112 matched HC in the international multicenter Parkinson's Progression Marker Initiative. Baseline clinical and demographic variables, PD medications, neuroimaging, and genetic variables were evaluated as potential predictors of CSF biomarker changes.
resultsCSF biomarkers were stable over 6 and 12 months, and there was a small but significant increase in CSF Aβ42 in both patients with patients with PD and HC from baseline to 12 months. The t-tau remained stable. The p-tau increased marginally more in patients with PD than in HC. α-syn remained relatively stable in patients with PD and HC. Ratios of p-tau/t-tau increased, while t-tau/Aβ42 decreased over 12 months in patients with PD. CSF biomarker changes did not correlate with changes in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale motor scores or dopamine imaging. CSF α-syn levels at 12 months were lower in patients with PD treated with dopamine replacement therapy, especially dopamine agonists.
conclusionsThese core CSF biomarkers remained stable over 6 and 12 months in patients with early PD and HC. PD medication use may influence CSF α-syn. Novel biomarkers are needed to better profile progressive neurodegeneration in PD.
Indexed as
AgedAmyloid beta-PeptidesApolipoproteins ECase-Control StudiesDopamineFemaleHumansLongitudinal StudiesMaleMiddle AgedParkinson DiseasePeptide FragmentsPolymorphism, Single NucleotideRetrospective StudiesSeverity of Illness Indextau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)Apolipoproteins EDopaminePeptide Fragmentstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.